December 6, 2010 (Orlando, Florida) - The results are preliminary, but a new tyrosine kinase
online pharmacy has shown promise in patients with refractory hematologic malignancies. The investigational agent, ponatinib (developed by ARIAD Pharmaceuticals), is a potent pan-BCR-ABL inhibitor that has demonstrated activity against all tested mutants
(
Read more... )